ClinicalTrials.gg
CompletedNCT02141854Updated Nov 9, 2021Results posted

Efficacy and Safety Study of FP MDPI Compared With FS MDPI in Adolescent and Adult Patients With Persistent Asthma

A Phase 3 interventional study of FS MDPI and Fp MDPI in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 154 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
882
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.

Enrollment
11th of 146
882 · median 100
Started
2014
with 8 others
Phase 3
35 of 147
none open now
Registered
105th of 147
by date
Lead sponsor
10 of 147
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 147 studies testing fluticasone in Asthma, this one is the 11th largest by enrollment of the 146 interventional ones that give a count, is one of 9 that started in 2014, is one of 35 in phase 3, and was the 105th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About fluticasone

Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 147 studies testing fluticasone in Asthma, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of fluticasone propionate (Fp) multidose dry powder inhaler (MDPI) and fluticasone propionate/salmeterol xinafoate (FS) MDPI when administered over 12 weeks in patients 12 years of age and older with persistent asthma.

Read the detailed description

Study drug and placebo were supplied in Teva multidose dry powder inhaler (MDPI) devices and provided for participants to use at home. Participants performed spirometry at every visit. Each participant was given a diary at each visit for use until the next visit. Rescue medication (albuterol/salbutamol) was dispensed at each visit, if needed, as determined by the investigational center personnel.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Best pre-bronchodilator (FEV1) of 40 to 85% of their predicted normal value.
  2. Current Asthma Therapy: Patients must have a short-acting β2-agonist (for rescue use) for a minimum of 8 weeks before the Screening Visit (SV) and a qualifying dose of an inhaled (ICS). The ICS may be either as ICS monotherapy or as an ICS/long-acting beta agonist (LABA) combination. The ICS component of the patient's asthma therapy should be stable for a minimum of 1 month before providing consent.
  3. Reversibility of Disease: Patients must have at least 15% reversibility (all patients) and at least a 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2 to 4 inhalations of albuterol/salbutamol at the SV. Note: Patients who do not qualify for the study due to failure to meet reversibility will be permitted to perform a retest once within 7 days.
  4. Patients must provide written /assent.. For minor patients (ages 12 to 17 years, or as applicable per local regulations), the written ICF must be signed and dated by the parent/legal guardian and the written assent form must be signed and dated by the patient (if applicable). Note: Age requirements are as specified by local regulations.
  5. Outpatient >= 12 years of age on the date of consent/assent. In countries where the local regulations permit enrollment of adult patients only, patients must be 18 years of age and older.
  6. Asthma diagnosis: The patient has a diagnosis of asthma as defined by the National Institute of Health (NIH). The asthma diagnosis has been present for a minimum of 3 months and has been stable (defined as no exacerbations and no changes in asthma medication) for at least 30 days.
  7. The patient is able to perform acceptable and repeatable spirometry.
  8. The patient is able to perform peak expiratory flow (PEF) with a handheld peak flow meter.
  9. The patient is able to use a metered dose inhaler (MDI) device without a spacer device and a multidose dry powder inhaler (MDPI) device.
  10. The patient is able to withhold (as judged by the investigator) his or her regimen of ICS or study drug, and rescue medication for at least 6 hours before the screening visit (SV) and before all treatment visits.
  11. The patient/parent/legal guardian/caregiver is capable of understanding the requirements, risks, and benefits of study participation, and, as judged by the investigator, capable of giving informed consent/assent and being compliant with all study requirements.
  12. SABAs: All patients must be able to replace their current SABA with albuterol/salbutamol HFA MDI inhalation aerosol for the duration of the study.
  13. Female patients may not be pregnant, breastfeeding, or attempting to become pregnant.

    • other criteria may apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  1. A history of a life-threatening asthma exacerbation (an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest, or hypoxic seizures).
  2. The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the study.
  3. The patient has participated as a randomized patient in any drug study within 30 days of the SV.
  4. The patient has previously participated as a randomized patient in a study of Fp MDPI or FS MDPI.
  5. The patient has a known to any , salmeterol, or any of the in the study drug or rescue medication formulation (ie, lactose).
  6. The patient has been treated with any known strong cytochrome P450 (CYP) 3A4 inhibitors (eg, azole antifungals, ritonavir, or clarithromycin) within 30 days before the SV.
  7. The patient has been treated with any of the prohibited medications during the prescribed (per protocol) before the SV.
  8. The patient currently smokes or has a smoking history of 10 pack years or more (a pack year is defined as smoking 1 pack of cigarettes/day for 1 year). The patient must not have used tobacco products within the past year (eg, cigarettes, cigars, chewing tobacco, or pipe tobacco).
  9. The patient has a culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus, or middle ear that has not resolved at least 2 weeks before the SV.
  10. The patient has a history of alcohol or drug abuse within 2 years preceding the SV.
  11. The patient has had an asthma exacerbation requiring systemic corticosteroids within 30 days before the SV, or has had any hospitalization for asthma within 2 months before the SV.
  12. Initiation or dose escalation of immunotherapy (administered by any route) is planned during the study period. However, patients on stable immunotherapy may be considered for inclusion.
  13. The patient has used medications within 4 weeks before the SV.
  14. The patient is unable to tolerate or unwilling to comply with the appropriate washout periods and withholding of all applicable medications.
  15. The patient has untreated oral candidiasis at the SV. Patients with clinical visual evidence of oral candidiasis who agree to receive treatment and comply with appropriate medical monitoring may enter the study.
  16. The patient has a history of a positive test for (HIV), active virus, or infection.
  17. The patient is either an employee or an immediate relative of an employee of the clinical investigational center.
  18. A member of the patient's household is participating in the study at the same time. However, after the enrolled patient completes or discontinues participation in the study, another patient from the same household may be screened.
  19. The patient has a disease/condition that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.

    • other criteria may apply, please contact the investigator for more information
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
882 participants (actual)

Study arms

  • Experimental
    FS MDPI 200 / 12.5 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 200 mcg (for a total daily dose of 400 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.

    Drug: FS MDPI · Drug: Albuterol/salmeterol HFA MDI

  • Experimental
    FS MDPI 100 / 12.5 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate 100 mcg (for a total daily dose of 200 mcg) and salmeterol 12.5 mcg (for a total daily dose of 25 mcg) for 12 weeks.

    Drug: FS MDPI · Drug: Albuterol/salmeterol HFA MDI

  • Experimental
    Fp MDPI 200 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 400 mcg for 12 weeks.

    Drug: Fp MDPI · Drug: Albuterol/salmeterol HFA MDI

  • Experimental
    Fp MDPI 100 mcg

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of fluticasone propionate (Fp) for a total daily dose of 200 mcg for 12 weeks.

    Drug: Fp MDPI · Drug: Albuterol/salmeterol HFA MDI

  • Placebo comparator
    Placebo MDPI

    Participants took 1 inhalation using a multidose dry powder inhaler (MDPI) twice a day of placebo for 12 weeks.

    Drug: Placebo MDPI · Drug: Albuterol/salmeterol HFA MDI

Interventions

  • FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Also known as: fluticasone propionate, inhaled corticosteroid, salmeterol xinafoate, β2 adrenoceptor agonist

  • Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg. Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Also known as: fluticasone propionate, inhaled corticosteroid

  • DrugPlacebo MDPI

    The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.

    Also known as: inert powder

  • DrugAlbuterol/salmeterol HFA MDI

    Drug page: Albuterol

    Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.

    Also known as: short-acting β2-adrenergic agonists

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12

    A subset of patients performed postdose serial spirometry. Data from these assessments were used to analyze the primary endpoint of baseline-adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.

    Time frame: Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours

  2. Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

    Trough FEV1 is a morning spirometry taken predose and pre-rescue bronchodilator. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).

    Time frame: Day 1 (predose, baseline), Week 12

Secondary outcomes

  1. Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment

    Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.

    Time frame: Days -6 to Day 1 (predose, baseline), Day 1 (postdose) daily until Week 12

  2. Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

    The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary. Daytime Symptom Score: * 0=No symptoms * 1=Symptoms for 1 short period * 2=Symptoms for 2+ short periods * 3=Symptoms for most of the day - did not affect normal daily activities * 4=Symptoms for most of the day - did affect normal daily activities * 5=Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): * 0=No symptoms * 1=Symptoms causing me to wake once (or wake early) * 2=Symptoms causing me to wake twice or more (including waking early) * 3=Symptoms causing me to be awake for most of the night * 4=Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).

    Time frame: Days -6 to Day 1 (predose, baseline), to Week 12

  3. Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period

    Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.

    Time frame: Days -6 to Day 1 (predose, baseline), up to week 12

  4. Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12

    The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

    Time frame: up to Week 12 of the Treatment Period

  5. Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old

    The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.

    Time frame: Day 1 (predose, baseline), end of trial (up to week 12)

  6. Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1

    The baseline forced expiratory volume in 1 second (FEV1) was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, the baseline trough FEV1 was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of NA indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.

    Time frame: Day 1 of the Treatment Period (predose and postdose)

  7. Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

    An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

    Time frame: Day 1 to Week 12 of the Treatment Period

07

Results

Posted Apr 12, 2017

Participant flow

Run-In Period (Pre-assignment)
Participant flow — Run-In Period (Pre-assignment)
MilestoneFluticasone Propionate 50 mcg BIDFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Started88200000
Completed72800000
Not completed15400000
Withdrew: Inclusion criteria not met2500000
Withdrew: Randomization criteria not met7600000
Withdrew: Exclusion criteria met1400000
Withdrew: Other1400000
Withdrew: Adverse event1000000
Withdrew: Withdrawal by subject900000
Withdrew: Lost to follow-up600000
Treatment Period
Participant flow — Treatment Period
MilestoneFluticasone Propionate 50 mcg BIDFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Started0146145146146145
Intent to treat population0146145146146145
Safety population0145143146145144
Full analysis set0145141146145143
Completed0136136135136107
Not completed0109111038
Withdrew: Protocol violation010221
Withdrew: Noncompliance000100
Withdrew: Lack of efficacy000117
Withdrew: Pregnancy010000
Withdrew: Other012012
Withdrew: Adverse event022022
Withdrew: Withdrawal by subject023347
Withdrew: Disease progression0213018
Withdrew: Lost to follow-up011101

Outcome measures

PrimaryStandardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12

A subset of patients performed postdose serial spirometry. Data from these assessments were used to analyze the primary endpoint of baseline-adjusted FEV1 AUEC0-12h at week 12 using the trapezoidal rule based on actual time of measurement. It was standardized by dividing it by the number of hours between the start time of dose administration and the end time of the last nonmissing FEV1 measurement. The baseline FEV1 was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose). If 1 of these was missing, the nonmissing value was used; if both were missing, baseline was treated as missing. Baseline-adjusted FEV1 was calculated as postdose FEV1 after subtracting the baseline FEV1 value.

Time frame:
Day 1 (predose, baseline), Week 12 and was performed at the following times relative to the administration of study drug (±5 minutes): 15 and 30 minutes and 1, 2, 3, 4, 6, 8, 10, and 12 hours
Reported as:
Least squares mean · liters
Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 12
litersFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Standardized Baseline-Adjusted Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time Zero to 12 Hours PostDose (FEV1 AUEC0-12) at Week 120.446 ± 0.04630.442 ± 0.04960.267 ± 0.04660.260 ± 0.04630.121 ± 0.0472
Statistical analysis
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · ANCOVA · p = 0.0009 (Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.) · Lsm difference: 0.179 · 95% CI 0.074 to 0.285
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · ANCOVA · p = 0.0010 (Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.) · Lsm difference: 0.182 · 95% CI 0.074 to 0.291
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.) · Lsm difference: 0.326 · 95% CI 0.221 to 0.431
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Fixed effects of treatment, sex, (pooled) center, previous therapy (ICS or ICS/LABA), and covariates of age and baseline FEV1.) · Lsm difference: 0.322 · 95% CI 0.212 to 0.432
PrimaryChange From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12

Trough FEV1 is a morning spirometry taken predose and pre-rescue bronchodilator. The baseline for predose FEV1 was defined as the average of the 30-minute and 10-minute predose measurements obtained at the randomization visit (Day 1).

Time frame:
Day 1 (predose, baseline), Week 12
Reported as:
Least squares mean · liters
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12
litersFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 120.272 ± 0.03070.271 ± 0.03110.179 ± 0.03080.119 ± 0.0311-0.004 ± 0.0312
Statistical analysis
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.) · Lsm difference: 0.276 · 95% CI 0.191 to 0.361
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.) · Lsm difference: 0.274 · 95% CI 0.189 to 0.360
  • Fp MDPI 200 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.) · Lsm difference: 0.183 · 95% CI 0.098 to 0.268
  • Fp MDPI 100 mcg vs Placebo MDPI · ANCOVA · p = 0.0047 (Effects due to baseline trough AM FEV1, sex, age, (pooled) center, previous therapy (ICS or ICS/LABA), and treatment.) · Lsm difference: 0.123 · 95% CI 0.038 to 0.208
SecondaryChange From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment

Morning PEF tests were performed before administration of study drug or rescue medications (data were excluded if the time of PEF measurement was more than 5 minutes after the dose time). The patient recorded the highest value of 3 measurements obtained in the patient diary. The baseline PEF was the average value of recorded (nonmissing) morning assessments over the 7 days prior to randomization on Day 1. For efficacy analyses of weekly average morning PEF measurements, values were the averages based on available data for that week.

Time frame:
Days -6 to Day 1 (predose, baseline), Day 1 (postdose) daily until Week 12
Reported as:
Least squares mean · liters/minute
Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment
liters/minuteFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Daily Morning Trough Peak Expiratory Flow (PEF) Over the 12 Week Treatment20.235 ± 2.384518.610 ± 2.41377.464 ± 2.38875.731 ± 2.4102-10.987 ± 2.4784
Statistical analysis
  • Fp MDPI 200 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 18.450 · 95% CI 11.751 to 25.150
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 16.718 · 95% CI 9.988 to 23.449
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 31.221 · 95% CI 24.513 to 37.930
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 29.597 · 95% CI 22.839 to 36.354
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · mixed model for repeated measures · p = 0.0002 (Significance level of 0.05.) · Lsm difference: 12.771 · 95% CI 6.179 to 19.363
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0002 (Significance level of 0.05.) · Lsm difference: 12.879 · 95% CI 6.216 to 19.541
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 200 mcg · mixed model for repeated measures · p = 0.0010 (Significance level of 0.05.) · Lsm difference: 11.146 · 95% CI 4.511 to 17.782
SecondaryChange From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period

The total daily asthma symptom score is the average of the daytime and nighttime scores as recorded in the patient diary. Daytime Symptom Score: * 0=No symptoms * 1=Symptoms for 1 short period * 2=Symptoms for 2+ short periods * 3=Symptoms for most of the day - did not affect normal daily activities * 4=Symptoms for most of the day - did affect normal daily activities * 5=Symptoms so severe that I could not go to work or perform normal daily activities Nighttime Symptom Score (determined in the AM): * 0=No symptoms * 1=Symptoms causing me to wake once (or wake early) * 2=Symptoms causing me to wake twice or more (including waking early) * 3=Symptoms causing me to be awake for most of the night * 4=Symptoms so severe that I did not sleep Baseline was the average of recorded scores over the 7 days before randomization. The change from baseline in the weekly average over weeks 1 to 12 was analyzed using an mixed model for repeated measures (MMRM).

Time frame:
Days -6 to Day 1 (predose, baseline), to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period
units on a scaleFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over the 12-Week Treatment Period-0.391 ± 0.0328-0.364 ± 0.0332-0.242 ± 0.0329-0.282 ± 0.0333-0.087 ± 0.0342
Statistical analysis
  • Fp MDPI 200 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0010 (Significance level of 0.05.) · Lsm difference: -0.156 · 95% CI -0.248 to -0.063
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.195 · 95% CI -0.288 to -0.102
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.304 · 95% CI -0.397 to -0.212
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.277 · 95% CI -0.370 to -0.184
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · mixed model for repeated measures · p = 0.0014 (Significance level of 0.05.) · Lsm difference: -0.149 · 95% CI -0.239 to -0.058
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0818 (Significance level of 0.05.) · Lsm difference: -0.082 · 95% CI -0.174 to 0.010
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 200 mcg · mixed model for repeated measures · p = 0.0094 (Significance level of 0.05.) · Lsm difference: -0.121 · 95% CI -0.213 to -0.030
SecondaryChange From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period

Patients recorded the number of inhalations of rescue medication (albuterol/salbutamol HFA MDI) each AM and PM in the diary. The average number of daily inhalations over the 7 days before the randomization visit was the baseline value. The weekly average was based on the available data for the 7 days before each analysis week. The change from baseline in the weekly average of total daily (24-hour) use of albuterol/ salbutamol inhalation aerosol (number of inhalations) over weeks 1 to 12 was analyzed using a mixed model for repeated measures.

Time frame:
Days -6 to Day 1 (predose, baseline), up to week 12
Reported as:
Least squares mean · puffs
Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period
puffsFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Change From Baseline in the Weekly Average of the Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol Over the 12-Week Treatment Period-0.898 ± 0.1069-0.821 ± 0.1080-0.534 ± 0.1070-0.439 ± 0.10810.168 ± 0.1102
Statistical analysis
  • Fp MDPI 200 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.702 · 95% CI -1.001 to -0.403
  • Fp MDPI 100 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0001 (Significance level of 0.05.) · Lsm difference: -0.607 · 95% CI -0.908 to -0.307
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -1.066 · 95% CI -1.365 to -0.766
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · mixed model for repeated measures · p = 0.0000 (Significance level of 0.05.) · Lsm difference: -0.989 · 95% CI -1.291 to -0.686
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · mixed model for repeated measures · p = 0.0160 (Significance level of 0.05.) · Lsm difference: -0.364 · 95% CI -0.659 to -0.068
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · mixed model for repeated measures · p = 0.0124 (Significance level of 0.05.) · Lsm difference: -0.382 · 95% CI -0.681 to -0.083
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 200 mcg · Wilcoxon (Mann-Whitney) · p = 0.0588 (Significance level of 0.05.) · Lsm difference: -0.287 · 95% CI -0.584 to 0.011
SecondaryKaplan-Meier Estimate of Probability of Remaining in Study At Week 12

The analysis of probability of remaining in the study at Week 12 used the time to patient withdrawal for worsening asthma, defined as the number of days elapsed from the date of randomization to the date of withdrawal due to worsening asthma. Patients who were lost to follow-up, who had not withdrawn due to worsening asthma by week 12, or who had withdrawn due to reasons other than worsening asthma were right-censored at the date of last assessment.

Time frame:
up to Week 12 of the Treatment Period
Reported as:
Number · probability
Kaplan-Meier Estimate of Probability of Remaining in Study At Week 12
probabilityFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Kaplan-Meier Estimate of Probability of Remaining in Study At Week 120.9719 (0.927 to 0.989)0.9929 (0.950 to 0.999)0.9786 (0.935 to 0.993)0.9930 (0.951 to 0.999)0.8528 (0.781 to 0.903)
Statistical analysis
  • Fp MDPI 200 mcg vs Placebo MDPI · Log Rank · p = 0.0001 (Significance level of 0.05.)
  • Fp MDPI 100 mcg vs Placebo MDPI · Log Rank · p = <.0001 (Significance level of 0.05.)
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · Log Rank · p = 0.0003 (Significance level of 0.05.)
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · Log Rank · p = <.0001 (Significance level of 0.05.)
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · Log Rank · p = 0.7203 (Significance level of 0.05.)
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · Log Rank · p = 0.9960 (Significance level of 0.05.)
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 200 mcg · Log Rank · p = 0.3250 (Significance level of 0.05.)
SecondaryChange From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old

The AQLQ(S) (September 2010 version; patients aged ≥18 years) was self administered by the patients at the investigational center at the randomization visit and at Week 12 or end of trial. The questionnaire is a tool to measure the impact of asthma on a patient's quality of life (physical, emotional, social, and occupational) with a recall period of 2 weeks. The AQLQ(S) was administered only to patients 18 years and older. The 32 individual questions in the AQLQ were equally weighted. The overall AQLQ score was the mean of the responses to each of the 32 questions, and ranged from 1 to 7. A score 7.0 indicated that the patient had no impairments due to asthma and a score of 1.0 indicated severe impairment. Positive change from baseline scores indicate improved quality of life.

Time frame:
Day 1 (predose, baseline), end of trial (up to week 12)
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old
units on a scaleFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
Change From Baseline in the Asthma Quality of Life Questionnaire With Standardized Activities (AQLQ(S)) Score at Endpoint for Patients >=18 Years Old0.534 ± 0.07410.592 ± 0.07250.384 ± 0.07420.340 ± 0.0740-0.089 ± 0.0747
Statistical analysis
  • Fp MDPI 200 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 0.473 · 95% CI 0.269 to 0.677
  • Fp MDPI 100 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 0.428 · 95% CI 0.224 to 0.632
  • FS MDPI 200 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Significance level of 0.05.) · Lsm difference: 0.623 · 95% CI 0.418 to 0.828
  • FS MDPI 100 / 12.5 mcg vs Placebo MDPI · ANCOVA · p = 0.0000 (Significance level of 0.05.) · Slope: 0.681 · 95% CI 0.478 to 0.885
  • FS MDPI 200 / 12.5 mcg vs Fp MDPI 200 mcg · ANCOVA · p = 0.1490 (Significance level of 0.05.) · Lsm difference: 0.150 · 95% CI -0.054 to 0.354
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 100 mcg · ANCOVA · p = 0.0143 (Significance level of 0.05.) · Lsm difference: 0.253 · 95% CI 0.051 to 0.455
  • FS MDPI 100 / 12.5 mcg vs Fp MDPI 200 mcg · ANCOVA · p = 0.0435 (Significance level of 0.05.) · Lsm difference: 0.209 · 95% CI 0.006 to 0.411
SecondaryKaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1

The baseline forced expiratory volume in 1 second (FEV1) was the average of the 2 predose FEV1 measurements (30 and 10 minutes predose) on Day 1. If one of these was missing, the other measurement was used as baseline value. If both were missing, the baseline trough FEV1 was treated as missing. Time to target improvement (15% or 12%) was defined as the time elapsed from the time of first dose to the first time the target improvement in FEV1 was achieved. If an exact target increase was not achieved at a measured timepoint, then the time was estimated by linear interpolation between the timepoint when target was reached and the timepoint immediately before. Patients who did not achieve the target improvement were censored at the time of last serial spirometry assessment. Values of NA indicate the values could not be estimated which happened when the estimated probability of not achieving target is more than 50%.

Time frame:
Day 1 of the Treatment Period (predose and postdose)
Reported as:
Median · hours
Kaplan-Meier Estimates for Time to 15% and 12% Improvement From Baseline in FEV1 Postdose on Day 1
hoursFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
15% improvement0.8 (0.310 to 1.770)0.9 (0.480 to 11.960)NA (3.840 to NA)NA (NA to NA)NA (NA to NA)
12% improvement0.4 (0.250 to 0.810)0.4 (0.290 to 1.680)6.9 (2.690 to NA)NA (5.580 to NA)NA (5.680 to NA)
SecondaryPatients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period

An adverse event was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Severity was rated by the investigator on a scale of mild, moderate and severe, with severe= an AE which prevents normal daily activities. Relation of AE to treatment was determined by the investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, OR an important medical event that jeopardized the patient and required medical intervention to prevent the previously listed serious outcomes.

Time frame:
Day 1 to Week 12 of the Treatment Period
Reported as:
Count of participants · Participants
Patients With Treatment-Emergent Adverse Experiences (TEAE) During the Treatment Period
ParticipantsFS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPI
>=1 TEAE6159605352
>=1 severe TEAE32011
>=1 treatment-related TEAE84965
>=1 severe treatment-related TEAE10000
>=1 serious TEAE22111
>=1 TEAE leading to withdrawal22022
>=1 nonserious TEAE6158605252
>=1 TEAE resulting in death01000

Adverse events

Collected over Day 1 up to Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FS MDPI 100/12.5 mcg—2/143 (1.4%)21/143 (14.7%)
FS MDPI 200/12.5 mcg—2/145 (1.4%)20/145 (13.8%)
Fp MDPI 100 mcg—1/145 (0.7%)26/145 (17.9%)
Fp MDPI 200 mcg—1/146 (0.7%)20/146 (13.7%)
Placebo—1/144 (0.7%)20/144 (13.9%)
Most frequent serious events
Most frequent serious events
EventFS MDPI 100/12.5 mcgFS MDPI 200/12.5 mcgFp MDPI 100 mcgFp MDPI 200 mcgPlacebo
JaundiceHepatobiliary disorders1/1430/1450/1450/1460/144
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1430/1450/1450/1460/144
AsthmaRespiratory, thoracic and mediastinal disorders0/1431/1450/1450/1461/144
PneumoniaInfections and infestations0/1431/1450/1450/1460/144
Grand mal convulsionNervous system disorders0/1430/1451/1450/1460/144
PyrexiaGeneral disorders0/1430/1450/1451/1460/144
Most frequent other events
Most frequent other events
EventFS MDPI 100/12.5 mcgFS MDPI 200/12.5 mcgFp MDPI 100 mcgFp MDPI 200 mcgPlacebo
HeadacheNervous system disorders6/1434/14511/1457/1467/144
NasopharyngitisInfections and infestations10/14310/1457/1457/1468/144
Upper respiratory tract infectionInfections and infestations6/1436/1459/1458/1467/144

Baseline characteristics

Randomized participants

Age, Continuous
Age, Continuous(years)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Mean44.7 ± 16.9344.3 ± 14.8844.4 ± 16.3645.7 ± 15.6444.5 ± 16.0544.7 ± 15.95
Age, Customized
Age, Customized(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Adolescents (12-17 years)128109645
Adults (18-64 years)115125119124125608
Adults (65-84 years)191217131475
Sex: Female, Male
Sex: Female, Male(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Female8779889491439
Male5966585254289
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
White125112116111124588
Black or African American2028233118120
Asian002024
American Indian or Alaskan Native002002
Native Hawaiian or Other Pacific Islander000000
Other1534114
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Not Hispanic or Latino136135136134136677
Hispanic or Latino10101011849
Unknown000112
History of Smoking
History of Smoking(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Prior Smoker2028212823120
No tobacco use126117125118122608
Previous Asthma Therapy
Previous Asthma Therapy(Participants)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Inhaled corticosteroid7367635868329
Inhaled corticosteroid/long-acting beta2-agonist7378838877399
Body Mass Index
Body Mass Index(kg/m^2)FS MDPI 200 / 12.5 mcgFS MDPI 100 / 12.5 mcgFp MDPI 200 mcgFp MDPI 100 mcgPlacebo MDPITotal
Mean29.4 ± 7.3530.2 ± 7.6029.9 ± 7.2729.9 ± 7.6229.3 ± 7.4129.7 ± 7.44

1 further baseline measures are reported on the registry.

08

Study locations

154 sites
  • Teva Investigational Site 12429
    Birmingham, Alabama, United States
  • Teva Investigational Site 12599
    Little Rock, Alaska, United States
  • Teva Investigational Site 12609
    Phoenix, Arizona, United States
  • Teva Investigational Site 12445
    Costa Mesa, California, United States
  • Teva Investigational Site 12454
    Encinitas, California, United States
  • Teva Investigational Site 12456
    Fresno, California, United States
  • Teva Investigational Site 12461
    Fullerton, California, United States
  • Teva Investigational Site 12410
    Huntington Beach, California, United States
  • Teva Investigational Site 12452
    Huntington Beach, California, United States
  • Teva Investigational Site 12417
    Long Beach, California, United States
  • Teva Investigational Site 13017
    Mission Viejo, California, United States
  • Teva Investigational Site 12462
    Rancho Mirage, California, United States
  • Teva Investigational Site 12411
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 13018
    San Diego, California, United States
  • Teva Investigational Site 12413
    San Jose, California, United States
  • Teva Investigational Site 12403
    Stockton, California, United States
  • Teva Investigational Site 12444
    Upland, California, United States
  • Teva Investigational Site 12999
    Vista, California, United States
  • Teva Investigational Site 12405
    Centennial, Colorado, United States
  • Teva Investigational Site 12419
    Centennial, Colorado, United States
  • Teva Investigational Site 13000
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 12459
    Waterbury, Connecticut, United States
  • Teva Investigational Site 13004
    Largo, Florida, United States
  • Teva Investigational Site 12414
    Miami, Florida, United States
  • Teva Investigational Site 12437
    Miami, Florida, United States
  • Teva Investigational Site 12427
    Orlando, Florida, United States
  • Teva Investigational Site 12423
    Ormond Beach, Florida, United States
  • Teva Investigational Site 12604
    Panama City, Florida, United States
  • Teva Investigational Site 13316
    Tamarac, Florida, United States
  • Teva Investigational Site 12606
    Winter Park, Florida, United States
  • Teva Investigational Site 12435
    Savannah, Georgia, United States
  • Teva Investigational Site 13315
    Eagle, Idaho, United States
  • Teva Investigational Site 12439
    River Forest, Illinois, United States
  • Teva Investigational Site 12449
    Shiloh, Illinois, United States
  • Teva Investigational Site 12457
    South Bend, Indiana, United States
  • Teva Investigational Site 12446
    Bangor, Maine, United States
  • Teva Investigational Site 12602
    Columbia, Maryland, United States
  • Teva Investigational Site 12432
    Fall River, Massachusetts, United States
  • Teva Investigational Site 12441
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 12466
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 13001
    Royal Oak, Michigan, United States
  • Teva Investigational Site 12428
    Ypsilanti, Michigan, United States
  • Teva Investigational Site 13020
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 12451
    Columbia, Missouri, United States
  • Teva Investigational Site 12421
    Rolla, Missouri, United States
  • Teva Investigational Site 12412
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12453
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12610
    Missoula, Montana, United States
  • Teva Investigational Site 13021
    Las Vegas, Nevada, United States
  • Teva Investigational Site 12409
    Skillman, New Jersey, United States
  • Teva Investigational Site 12603
    Bronx, New York, United States
  • Teva Investigational Site 12464
    Brooklyn, New York, United States
  • Teva Investigational Site 12430
    Charlotte, North Carolina, United States
  • Teva Investigational Site 12407
    Raleigh, North Carolina, United States
  • Teva Investigational Site 12415
    Canton, Ohio, United States
  • Teva Investigational Site 12455
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12463
    Cincinnati, Ohio, United States
  • Teva Investigational Site 12460
    Middleburg Heights, Ohio, United States
  • Teva Investigational Site 12426
    Edmond, Oklahoma, United States
  • Teva Investigational Site 13008
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12406
    Medford, Oregon, United States
  • Teva Investigational Site 12442
    Portland, Oregon, United States
  • Teva Investigational Site 12563
    Normal, Pennsylvania, United States
  • Teva Investigational Site 12443
    Pittsburgh, Pennsylvania, United States
  • Teva Investigational Site 12438
    Upland, Pennsylvania, United States
  • Teva Investigational Site 12408
    Charleston, South Carolina, United States
  • Teva Investigational Site 12431
    Greenville, South Carolina, United States
  • Teva Investigational Site 12465
    Mount Pleasant, South Carolina, United States
  • Teva Investigational Site 12467
    Mount Pleasant, South Carolina, United States
  • Teva Investigational Site 12420
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 12433
    Rock Hill, South Carolina, United States
  • Teva Investigational Site 13003
    Knoxville, Tennessee, United States
  • Teva Investigational Site 12425
    Arlington, Texas, United States
  • Teva Investigational Site 12416
    Dallas, Texas, United States
  • Teva Investigational Site 12418
    Dallas, Texas, United States
  • Teva Investigational Site 12440
    El Paso, Texas, United States
  • Teva Investigational Site 12447
    Killeen, Texas, United States
  • Teva Investigational Site 13318
    San Antonio, Texas, United States
  • Teva Investigational Site 13002
    Sugar Land, Texas, United States
  • Teva Investigational Site 12424
    Waco, Texas, United States
  • Teva Investigational Site 12422
    South Burlington, Vermont, United States
  • Teva Investigational Site 12605
    Richmond, Virginia, United States
  • Teva Investigational Site 12436
    Spokane, Washington, United States
  • Teva Investigational Site 12564
    Tacoma, Washington, United States
  • Teva Investigational Site 12448
    Greenfield, Wisconsin, United States
  • Teva Investigational Site 11072
    Toronto, Ontario, Canada
  • Teva Investigational Site 11075
    Vancouver, Quebec, Canada
  • Teva Investigational Site 54096
    Jindrichuv Hradec, Czechia
  • Teva Investigational Site 54098
    Praha, Czechia
  • Teva Investigational Site 54095
    Rokycany, Czechia
  • Teva Investigational Site 54094
    Strakonice, Czechia
  • Teva Investigational Site 51149
    Budapest, Hungary
  • Teva Investigational Site 51155
    Budapest, Hungary
  • Teva Investigational Site 51157
    Budapest, Hungary
  • Teva Investigational Site 51161
    Budapest, Hungary
  • Teva Investigational Site 51154
    Debrecen, Hungary
  • Teva Investigational Site 51152
    Deszk, Hungary
  • Teva Investigational Site 51170
    Dombovar, Hungary
  • Teva Investigational Site 51158
    Kiskunhalas, Hungary
  • Teva Investigational Site 51153
    Miskolc, Hungary

Showing the first 100 of 154 sites across 9 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Sher LD, Yiu G, Sakov A, Liu S, Caracta CF. Fluticasone propionate and fluticasone propionate/salmeterol multidose dry powder inhalers compared with placebo for persistent asthma. Allergy Asthma Proc. 2017 Sep 21;38(5):343-353. doi: 10.2500/aap.2017.38.4069. Epub 2017 Jun 21. PubMed 28639542 ↗
  • Miller DS, Yiu G, Hellriegel ET, Steinfeld J. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016 Jul;37(4):291-301. doi: 10.2500/aap.2016.37.3963. Epub 2016 May 27. PubMed 27216137 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2014, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 9, 2014
First posted
May 20, 2014
Start
Jun 2014
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Apr 12, 2017
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02141854
Responsible party
Sponsor
First posted
May 20, 2014
Start date
Jun 2014
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Apr 12, 2017
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluticasone

Start the discussion